Abstracts tagged "differential diagnosis and rheumatoid arthritis (RA)"

Abstract Number: 2585 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3η Is an RA Specific Mechanistic Marker
Bidisha Dasgupta¹, Yauheniya Cherkas¹, Sarah Lamberth¹, Karen Hayden¹, Carrie Brodmerkel¹, Anthony Marotta² and Mark Curran¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Augurex Life Sciences Corp., Vancouver, BC, Canada
Background/Purpose: 14-3-3η is an emerging soluble Rheumatoid Arthritis (RA) biomarker that activates intracellular pathways that lead to the upregulation of inflammatory and joint damage factors.…
Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting
Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Nathalie Carrier¹, Anthony Marotta², Artur de Brum-Fernandes^3,4, Patrick Liang^3,4, Ariel Masetto^5,6, Yuan Gui², Jane Savill², Sara Michienzi², Henri Ménard⁷, Walter Maksymowych⁸ and Gilles Boire⁴, ¹Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].